Drug Profile
Research programme: colony stimulating factor 1 receptor antagonists - Daiichi Sankyo
Alternative Names: AC710Latest Information Update: 22 Feb 2023
Price :
$50
*
At a glance
- Originator Ambit Biosciences Corporation
- Developer Daiichi Sankyo Company
- Class Small molecules
- Mechanism of Action Macrophage colony stimulating factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Cancer; Inflammation
Most Recent Events
- 22 Feb 2023 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 22 Feb 2023 Discontinued - Preclinical for Inflammation in USA (unspecified route)
- 28 May 2018 No recent reports of development identified for preclinical development in Cancer in USA